---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342524"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2026-08-10T20:35:51+00:00"
generated_at: "2026-08-10T20:37:11.592836+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Annexon appoints Mark Blumenkranz to board; Muneer Satter steps down after 11 years

## Summary
- Mark S. Blumenkranz appointed to Annexon board effective Aug 10, 2026, as Class II director with term to 2028 annual meeting.
- He joins Audit Committee and Science and Technology Committee; receives $40k annual retainer and 175k-share initial option grant.
- Muneer Satter resigned as director and committee roles effective immediately prior to Blumenkranz appointment; no disagreement cited.
- Blumenkranz is Stanford emeritus professor; co-founded Adverum, Optimedica, Oculeve, Kedalion; retinal expertise relevant to vonaprument.

## SEC filing metadata
- accession: 0001193125-26-342524
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2026-08-10T20:35:51+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/0001193125-26-342524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/d130710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342524
- JSON: https://secwatch.observer/filing/0001193125-26-342524.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.